Pelthos Therapeutics Inc.
AMEX:PTHSBiotechnology
-$0.37 today
- Market cap
- $63.32M
- Beta
- 3.13
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$15.58
Volume 0.01M
Average 0.04M
PTHS Long-term Debt
Borrowings due after more than one year.
Pelthos Therapeutics Inc.AMEX: PTHS
Long-term Debt · Q1 FY2026 · quarter ended Mar 2026
Long-term debt remains negative
Q1 FY2026 long-term debt was $49.64M, compared with $0 a year earlier.
Context
- Long-term debt amounted to 34.1% of total assets at the end of Q1 FY2026, up 34.1 pp from a year earlier.
- Long-term debt increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 31.44M USD
- Year-over-year change
- —
| Period | Period end | Long-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 31.44M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Long-term Debt vs competitors
How PTHS compares with its peers on the latest reported figures
- PTHS's Mar 2026 long-term debt of $49.64M is the highest of the 4 companies compared; the peer median is $0.
- Long-term debt amounts to 34.1% of total assets for PTHS, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $49.64M | — | — | 34.1% | |
| Mar 2026 | $461.77K | — | — | 4.2% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Dec 2025 | $0 | — | — | 0.0% | |
| Peer median (excluding PTHS) | $0 | -100.0% | — | 0.0% | |
Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Pelthos Therapeutics Inc.
AMEX:PTHS
Intrinsic Alpha fair value
Locked
Current Price
$16.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.